Next Article in Journal
Targeted Protein Degradation by Chimeric Compounds using Hydrophobic E3 Ligands and Adamantane Moiety
Previous Article in Journal
Grаdiеnt HPLC Mеthоd fоr Simultаnеоus Dеtеrminаtiоn оf Еight Sаrtаn аnd Stаtin Drugs in Thеir Purе аnd Dоsаgе Fоrms
Open AccessReview

Advances in CXCR7 Modulators

Department of Pharmaceutical Sciences, Larkin University College of Pharmacy, Miami, FL 33169, USA
Pharmaceuticals 2020, 13(2), 33; https://doi.org/10.3390/ph13020033
Received: 15 January 2020 / Revised: 17 February 2020 / Accepted: 19 February 2020 / Published: 21 February 2020
(This article belongs to the Section Medicinal Chemistry)
CXC chemokine receptor 7 (CXCR7) is a G-protein-coupled receptor that signals through the β-arrestin pathway. Its ligands include interferon-inducible T cell α chemoattractant (CXCL11) and stromal cell-derived factor-1 (CXCL12). It interacts with CXCR4, and the two are associated with various cancers, as well as other disease states such as coronary artery disease, stroke, inflammation and human immunodeficiency virus (HIV). Antibodies and small interfering RNA (siRNA) have shown the utility of antagonists of CXCR7 in these disease states. Although some small molecules were initially reported as antagonists due to their displayed activity, many function as agonists while still producing the desired pharmacologic effects. A potential reason for this contradiction is that effects may be due to elevated extracellular CXCL12 levels. View Full-Text
Keywords: CXCR7; CXCL12; CXCR4 CXCR7; CXCL12; CXCR4
Show Figures

Figure 1

MDPI and ACS Style

Lounsbury, N. Advances in CXCR7 Modulators. Pharmaceuticals 2020, 13, 33.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop